NASDAQ:KNSA • GB00BRXB0C07
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KINIKSA PHARMACEUTICALS INTE (KNSA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-28 | Jefferies | Maintains | Buy -> Buy |
| 2026-04-16 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-25 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-19 | Canaccord Genuity | Initiate | Buy |
| 2026-01-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-29 | TD Cowen | Initiate | Buy |
| 2025-09-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-07-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-04-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-13 | Citigroup | Initiate | Buy |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-09-13 | Jefferies | Initiate | Buy |
| 2024-07-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-05-03 | Wells Fargo | Initiate | Overweight |
| 2024-05-01 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-24 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-01-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-26 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 270.259M 22.74% | 423.239M 56.60% | 677.564M 60.09% | 932.36M 37.60% | 1.098B 17.77% | 1.26B 14.75% | 1.382B 9.68% | 1.54B 11.43% | 1.775B 15.26% | 2.033B 14.54% | 2.513B 23.61% | |
| EBITDA YoY % growth | -22.855M -287.75% | -43.921M -92.17% | 78.775M 279.36% | 176.89M 124.55% | 228.2M 29.01% | 324.6M 42.24% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -25.196M -357.81% | -45.616M -81.04% | 77.221M 269.28% | 133.81M 73.28% | 179.28M 33.98% | 207.79M 15.90% | 296.23M 42.56% | 470.55M 58.85% | 766.86M 62.97% | 1.022B 33.27% | 1.402B 37.18% | |
| Operating Margin | -9.32% | -10.78% | 11.40% | 14.35% | 16.33% | 16.49% | 21.43% | 30.56% | 43.20% | 50.27% | 55.79% | |
| EPS YoY % growth | 0.18 -93.05% | -0.61 -438.89% | 0.74 221.31% | 1.10 49.06% | 1.64 49.05% | 2.47 50.45% | 3.19 28.87% | 4.68 46.72% | 7.54 61.29% | 10.83 43.61% | 17.71 63.47% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.26 14.67% | 0.30 32.41% | 0.39 127.14% | 0.36 32.22% | 0.40 50.83% | 0.42 37.32% | 0.43 10.94% |
| Revenue Q2Q % growth | 226.68M 44.57% | 240.58M 33.02% | 253.14M 25.24% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 26.131M 25.25% | 31.879M 26.97% | 51.868M 143.26% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 29.099M 44.34% | 34.644M 44.22% | 43.365M 119.37% | N/A | N/A | N/A | N/A |
All data in USD
14 analysts have analysed KNSA and the average price target is 57.7 USD. This implies a price increase of 7.72% is expected in the next year compared to the current price of 53.565.
The consensus EPS estimate for the next earnings of KINIKSA PHARMACEUTICALS INTE (KNSA) is 0.26 USD and the consensus revenue estimate is 226.68M USD.
The expected long term growth rate for KINIKSA PHARMACEUTICALS INTE (KNSA) is 22.23%.